ALSO NOTED: FDA assails King promo for omitted risks; Schering drug approval boosts stock;

> Boehringer Ingelheim has stolen a march on arch rival Bayer, winning European marketing approval for a new anti-clotting agent--Pradaxa--that is likely to provide Lovenox with considerable competition. Report

> The FDA warned King Pharmaceuticals that a promotional brochure for its painkiller Avinza was "false or misleading" because it overstated the drug's effectiveness and downplayed its risks; the promo card completely left out the boxed warning that's part of Avinza's labeling. FDA called the omissions "egregious and alarming." Report

> Schering-Plough shares ballooned by 3.2 percent to $19.30 yesterday, on news that the FDA gave its OK to Schering's antiviral drug Rebetol for treatment of hepatitis C. Report

> Atypical antipsychotics are no better than their older rivals at managing a first schizophrenic episode, according to a new study in The Lancet. Report

> A Sanofi-Aventis-funded study showed that the company's once-daily insulin shot Lantus controlled blood sugar in type 2 diabetes patients as well as insulin varieties requiring three shots per day. Report

> Actavis won the FDA's nod for its generic extended release Wellbutrin for use as an antidepressant and a stop-smoking remedy. Release

> Drug makers spent more than $16 million on hospitality and travel for Australian doctors and nurses over the last six months of 2007, new required disclosures show. Report

> The FDA is warning consumers that two dietary supplements--Total Body Formula and Total Body Mega Formula--are being recalled after 23 people suffered serious reactions, including significant hair loss and diarrhea. Report

Most popular this week: Companies saw Vytorin threat in 2005. Report

And Finally... What should patients with a sinus infection do? Wait until it goes away, a new study says. Report

Suggested Articles

Post-Tesaro buyout, don’t expect GlaxoSmithKline to spring for more commercial-stage oncology products anytime soon.

Already a fast-growing blockbuster, Novo Nordisk's injectable Ozempic won a major heart-helping FDA nod that could bode well for its oral sibling.

Bayer's new Vitrakvi for tumors with NTRK gene fusions is meeting skepticism in England and Germany, where cost watchdogs on Friday rejected it.